血管抑素的功能及其在慢性肾脏病中的作用  

Function of angiostatin and its role in chronic kidney disease

作　　者：夏园园 蔡广研[1] Xia Yuanyuan;Cai Guangyan(Department of Nephrology,Chinese PLA General Hospital,Chinese PLA Institute of Nephrology,State Key Laboratory of Kidney Diseases,National Clinical Researeh Center jbr Kidney Diseases,Beijing 100853,China Corresponding author ： Cai Guangyan,Email ： caiguangyan@ sina.com)

机构地区：[1]解放军总医院肾脏病科、解放军肾脏病研究所、肾脏疾病国家重点实验室、国家慢性肾病临床医学研究中心,北京100853

出　　处：《中华肾病研究电子杂志》2017年第2期79-82,共4页Chinese Journal of Kidney Disease Investigation（Electronic Edition）

基　　金：国家科技支撑计划课题(2015BAI12B06,2011BAI10B03);国家973计划课题(2013CB530805);863课题(2012AA02A512);国家自然科学基金(81171645)

摘　　要：慢性肾脏病进展至终末期肾病及需行肾脏替代治疗的患者数目逐年增加。血管生成因子和内源性血管抑制因子表达失调在慢性肾脏病进展中发挥着重要作用。血管抑素是内源性血管生成抑制剂,是纤溶酶原的蛋白水解产物。血管抑素兼具抑制血管生成和抗炎作用,在非糖尿病肾病,其表现为抑制肾小管外周血管形成、减慢血流速度作用;在糖尿病肾病早期其抑制血管内皮生长因子-A(VEGF-A)和转化生长因子-β(TGF-β)表达发挥治疗作用。本文就血管抑素的结构、作用及其在慢性肾脏病中的作用研究进行综述。The number of patients with chronic kidney disease （CKD） that develops to end-stage renal disease （ESRD） and requires renal replacement therapy is increasing year by year. Angiogenesis factors and endogenous angiogenesis inhibitors play- important roles in the progression of CKD. Angiostatin is an endogenous angiogenesis inhibitor and a proteolytie product of plasminogen. Angiostatin has anti- angiogenesis and anti-ilfflamnlatory effects, which inhibits renal tubular peripheral vascular formation and slows down blood flow velocity in non-diabetic nephropathy. In the early stage of diabetic nephropathy, angiostatin exerts its therapeutic effects by inhibiting the expression of vascular endothelial growth factor-A （VEGF-A） and transforming growth factor-β （TGF-β1 ）. This review discussed the structure and function of angiostatin and its role in CKD in order to discover the role of angiostatin in progression of CKD.

关 键 词：血管抑素 慢性肾脏病 血管生成 抗炎 肾小管周毛细血管损伤 

分 类 号：R692[医药卫生—泌尿科学]